Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal.

Slides:

Advertisements

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Advertisements

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Meta-analysis of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection Na Huang, M.S., Bing Situ, M.S., Xiao.

Antagonists in poor-responder patients

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone.

J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casañ, F

Pseudocyesis The Journal for Nurse Practitioners

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Treating endometriosis as an autoimmune disease

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Hongxia Li, M. D. , Jiangang Chen, M. D. , James W Overstreet, M. D

Analysis of the Cys82Arg mutation in follicle-stimulating hormone beta (FSHβ) using a novel FSH expression vector Andrew D Clark, Lawrence C Layman,

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women Ioannis E. Messinis, M.D., Ph.D.,

Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle James R. Stelling, M.D., Emily.

Zeev Shoham, M.D. Fertility and Sterility

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Microdose follicular phase gonadotropin-releasing hormone agonists (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization5

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Conversion of high-response gonadotropin intrauterine insemination cycles to in vitro fertilization results in excellent ongoing pregnancy rates Amy.

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

Effect of rejuvenation hormones on spermatogenesis

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Yuan-qing Yao, M.D., Pak-chung Ho, M.D., William Shu-biu Yeung, Ph.D.

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Bo Yu, M.D., Jane Ruman, M.D., Gregory Christman, M.D.

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study Carlo.

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Relationship between sleep and secretion of gonadotropin and ovarian hormones in women with normal cycles Sandrine Touzet, M.D., Muriel Rabilloud, M.D.,

Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment

Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part II. dose-proportionality and gonadotropin suppression after.

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Predictive usefulness of cycle day 10 follicle-stimulating hormone level in a clomiphene citrate challenge test for in vitro fertilization outcome in.

Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series Nanette L. Rollene,

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Circulating Bioactive and Immunoreactive Recombinant Human Follicle-Stimulating Hormone (Org 32489) After Administration to Gonadotropin-Deficient Subjects

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Value of the serum estradiol level on the day of human chorionic gonadotropin injection and on the day after in predicting the outcome in natural in vitro.

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization Efstratios M Kolibianakis, M.D., Kostas.

Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil.,

Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: Comparison of a new formulation.

A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human.

Gonadotropin preparations: past, present, and future perspectives

Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.

First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.

Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function David H. Barad, M.D., M.S., Andrea Weghofer,

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following.

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development

Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect.

Use of recombinant human chorionic gonadotropin in ovulation induction

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea

Presentation transcript:

Pharmacokinetics and pharmacodynamics of single-chain recombinant human follicle- stimulating hormone containing the human chorionic gonadotropin carboxyterminal peptide in the rhesus monkey Jeffrey Klein, M.D., Leslie Lobel, M.D., Ph.D, Susan Pollak, B.A., Michel Ferin, M.D., Ennian Xiao, M.D., Mark Sauer, M.D., Joyce W Lustbader, Ph.D. Fertility and Sterility Volume 77, Issue 6, Pages 1248-1255 (June 2002) DOI: 10.1016/S0015-0282(02)03113-8

FIGURE 1 Schematic of recombinant hFSH–CTP construct with locations of restriction sites. Klein. r-hFSH-CTP in rhesus monkeys. Fertil Steril 2002. Fertility and Sterility 2002 77, 1248-1255DOI: (10.1016/S0015-0282(02)03113-8)

FIGURE 2 In vitro bioassay of pituitary FSH (pFSH) as compared with recombinant hFSH–CTP in Y1 cells transfected with the FSH receptor. Klein. r-hFSH-CTP in rhesus monkeys. Fertil Steril 2002. Fertility and Sterility 2002 77, 1248-1255DOI: (10.1016/S0015-0282(02)03113-8)

FIGURE 3 Serial recombinant hFSH–CTP levels in four rhesus monkeys after a single SC injection at a dose of 10 IU/kg. Each symbol is representative of a different monkey. Klein. r-hFSH-CTP in rhesus monkeys. Fertil Steril 2002. Fertility and Sterility 2002 77, 1248-1255DOI: (10.1016/S0015-0282(02)03113-8)

FIGURE 4 Serial r-hFSH levels in two rhesus monkeys after a single SC injection at a dose of 10 IU/kg. Each symbol is representative of a different monkey. Klein. r-hFSH-CTP in rhesus monkeys. Fertil Steril 2002. Fertility and Sterility 2002 77, 1248-1255DOI: (10.1016/S0015-0282(02)03113-8)

FIGURE 5 Change in estradiol level in two normally cycling monkeys after a single SC injection of recombinant hFSH–CTP. Both monkeys were given the GnRH antagonist ganirelix acetate for the duration of the study. Klein. r-hFSH-CTP in rhesus monkeys. Fertil Steril 2002. Fertility and Sterility 2002 77, 1248-1255DOI: (10.1016/S0015-0282(02)03113-8)